Sasaki, TakaakiRodig, ScottChirieac, LucianJanne, Pasi2022-07-212010-07Sasaki, Takaaki, Scott Rodig, Lucian Chirieac, Pasi Janne. "The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer." European Journal of Cancer 46, no. 10 (2010): 1773-1780. DOI: 10.1016/j.ejca.2010.04.0020959-8049https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37372750The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.en-USResearch Subject Categories::MEDICINE::Morphology, cell biology, pathology::Morphology::Tumour biologyResearch Subject Categories::MEDICINE::Surgery::OncologyJournal Article2017-09-2220102022-07-2110.1016/j.ejca.2010.04.002